Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research

State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men

Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · see citing works

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978 · see citing works

Antibody Pharmacokinetics and Pharmacodynamics

Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909 · see citing works

The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery

Smith, D. A., Li, D.-Z., & Kerns, E. (2010) · Nature reviews. Drug discovery · doi:10.1038/nrd3287 · Cited by 864 · see citing works

Pharmacokinetic/pharmacodynamic data analysis : concepts and applications

Gabrielsson, J., & Weiner, D. (2002) · Cited by 704 · see citing works

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

Ambrose, P. G., Bhavnani, S. M., Rubino, C. M., Louie, A., Gumbo, T., Forrest, A., & Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/510079 · Cited by 697 · see citing works

Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies

Vaidya, V. S., Ozer, J. S., Dieterle, F., Collings, F. B., Ramírez, V., Troth, S. P., Muniappa, N., Thudium, D. T., Gerhold, D. L., Holder, D., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1623 · Cited by 662 · see citing works

Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents

Simeoni, M., Magni, P., Cammia, C., Nicolao, G. D., Croci, V., Pesenti, E. A., Germani, M., Poggesi, I., & Rocchetti, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2524 · Cited by 509 · see citing works

Elimination mechanisms of therapeutic monoclonal antibodies

Tabrizi, M. A., Tseng, C.-M. L., & Roskos, L. K. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03638-x · Cited by 479 · see citing works

BRAFV600E: Implications for Carcinogenesis and Molecular Therapy

Dorris, E., O’Leary, J. J., & Sheils, O. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0799 · Cited by 457 · see citing works

Model-based Drug Development

Lalonde, R. L., Kowalski, K., Hutmacher, M. M., Ewy, W., Nichols, D., Milligan, P. A., Corrigan, B., Lockwood, P. A., Marshall, S. A., Benincosa, L. J., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100235 · Cited by 452 · see citing works

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

Marsilje, T. H., Pei, W., Chen, B., Lu, W., Uno, T., Jin, Y., Jiang, T., Kim, S., Li, N., Warmuth, M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400402q · Cited by 422 · see citing works

Animal model pharmacokinetics and pharmacodynamics: a critical review

Andes, D. R., & Craig, W. A. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00022-5 · Cited by 415 · see citing works

Clinical pharmacokinetics and pharmacodynamics : concepts and applications

Rowland, M., & Tozer, T. N. (2011) · Cited by 366 · see citing works

Physiologic indirect response models characterize diverse types of pharmacodynamic effects

Jusko, W. J., & Ko, H. C. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.155 · Cited by 360 · see citing works

Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives

Derendorf, H., & Meibohm, B. (1999) · Pharmaceutical Research · doi:10.1023/a:1011907920641 · Cited by 352 · see citing works

The importance of plasma protein binding in drug discovery

Trainor, G. L. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.1.51 · Cited by 352 · see citing works

Tissue concentrations: do we ever learn?

Mouton, J. W., Theuretzbacher, U., Craig, W. A., Tulkens, P. M., Derendorf, H., & Cars, O. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm476 · Cited by 352 · see citing works

Diversity of Mechanism-Based Pharmacodynamic Models

Mager, D. E., Wyska, E., & Jusko, W. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.510 · Cited by 345 · see citing works

Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery

Meister, S., Plouffe, D., Kuhen, K., Bonamy, G. M. C., Wu, T., Barnes, S. W., Bopp, S. E. R., Borboa, R., Bright, A. T., Che, J., et al. (2011) · Science · doi:10.1126/science.1211936 · Cited by 341 · see citing works

Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding.

Waters, N., Jones, R., Williams, G., & Sohal, B. (2008) · Journal of Pharmacy and Science · doi:10.1002/jps.21317 · Cited by 322 · see citing works

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

Danhof, M., DELANGE, E., Pasqua, O. E. D., Ploeger, B. A., & Voskuyl, R. A. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.01.007 · Cited by 287 · see citing works

Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development

van der Graaf, P. H., & Benson, N. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0467-9 · Cited by 247 · see citing works

Use of Plasma and Brain Unbound Fractions to Assess the Extent of Brain Distribution of 34 Drugs: Comparison of Unbound Concentration Ratios to in Vivo P-Glycoprotein Efflux Ratios

Kalvass, J. C., Maurer, T. S., & Pollack, G. M. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012294 · Cited by 227 · see citing works

Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100

Yu, R., Kim, T.-W., Hong, A., Watanabe, T., Gaus, H., & Geary, R. (2007) · Drug Metabolism And Disposition · doi:10.1124/dmd.106.012401 · Cited by 226 · see citing works

Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs

Ieiri, I., Higuchi, S., & Sugiyama, Y. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902976854 · Cited by 211 · see citing works

Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development

Derendorf, H., Lesko, L. J., Chaikin, P., Colburn, W. A., Lee, P., Miller, R., Powell, R., Rhodes, G. R., Stanski, D. R., & Venitz, J. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001211 · Cited by 207 · see citing works

Pharmacokinetics and the drug–target residence time concept

Dahl, G., & Åkerud, T. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.02.010 · Cited by 206 · see citing works

Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation

Chien, J. Y., Friedrich, S. W., Heathman, M. A., de Alwis, D. P., & Sinha, V. P. (2005) · The AAPS Journal · doi:10.1208/aapsj070355 · Cited by 178 · see citing works

Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development

MAHMOOD, I. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.015 · Cited by 170 · see citing works

Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing

Colburn, W. A. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003252480 · Cited by 150 · see citing works

How Modeling and Simulation Have Enhanced Decision Making in New Drug Development

Miller, R., Ewy, W., Corrigan, B., Ouellet, D., Hermann, D. J., Kowalski, K. G., LOCKWOOD, P. A., Koup, J. R., Donevan, S. D., El‐Kattan, A. F., et al. (2005) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-005-0074-7 · Cited by 147 · see citing works

The role of mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modelling in translational research of biologics

Agoram, B. M., Martin, S. W., & van der Graaf, P. H. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.002 · Cited by 143 · see citing works

Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans

Mager, D. E., Woo, S., & Jusko, W. J. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.16 · Cited by 141 · see citing works

Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro

Lobo, E. D., & Balthasar, J. P. (2002) · AAPS PharmSci · doi:10.1208/ps040442 · Cited by 127 · see citing works

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100

Yu, R. Z., Lemonidis, K. M., Graham, M. J., Matson, J. E., Crooke, R. M., Tribble, D. L., Wedel, M. K., Levin, A. A., & Geary, R. S. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.005 · Cited by 125 · see citing works

Development of Translational Pharmacokinetic–Pharmacodynamic Models

Mager, D. E., & Jusko, W. J. (2008) · Clinical pharmacology and therapy · doi:10.1038/clpt.2008.52 · Cited by 122 · see citing works

Clinical pharmacokinetics and pharmacodynamicsconcepts and applications

Tozer, M. R. A. T. N. (2009) · Cited by 120 · see citing works

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

Jumbe, N. L., Xin, Y., Leipold, D. D., Crocker, L., Dugger, D., Mai, E., Sliwkowski, M. X., Fielder, P. J., & Tibbitts, J. (2010) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-010-9156-2 · Cited by 119 · see citing works

Pharmacokinetic–Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation

Wong, H., Alicke, B., West, K. A., Pacheco, P., La, H., Januario, T., Yauch, R. L., de Sauvage, F. J., & Gould, S. E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0975 · Cited by 113 · see citing works

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics

Gibiansky, L. V., & Gibiansky, E. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902992901 · Cited by 111 · see citing works

Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations

Gabrielsson, J., Dolgos, H., Gillberg, P., Bredberg, U., Benthem, B., & Duker, G. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.12.011 · Cited by 104 · see citing works

PK/PD modelling and simulations: utility in drug development

Rajman, I. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.01.003 · Cited by 101 · see citing works

Prediction of Human Pharmacokinetic Profile in Animal Scale up Based on Normalizing Time Course Profiles

Wajima, T., Yano, Y., Fukumura, K., & Oguma, T. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20099 · Cited by 98 · see citing works

Plasma / Serum Protein Binding Determinations

Banker, M. J., & Clark, T. H. (2008) · Current Drug Metabolism · doi:10.2174/138920008786485065 · Cited by 95 · see citing works

Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models

Yamazaki, S., Skaptason, J., Romero, D., Lee, J. H., Zou, H. Y., Christensen, J. G., Koup, J. R., Smith, B. J., & Koudriakova, T. B. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019711 · Cited by 94 · see citing works

Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941

Salphati, L., Wong, H., Belvin, M. P., Bradford, D., Edgar, K. A., Prior, W. W., Sampath, D., & Wallin, J. J. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032912 · Cited by 84 · see citing works

CYP3A INDUCTION BY LIVER X RECEPTOR LIGANDS IN PRIMARY CULTURED RAT AND MOUSE HEPATOCYTES IS MEDIATED BY THE PREGNANE X RECEPTOR

Shenoy, S. D., Spencer, T. A., Mercer-Haines, N. A., Alipour, M., Gargano, M. D., Runge‐Morris, M., & Kocarek, T. A. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.1.66 · Cited by 82 · see citing works

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

Wong, H., Vernillet, L., Peterson, A., Ware, J. A., Lee, L., Martini, J., Yu, P., Li, C., Rosario, G. D., Choo, E. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0445 · Cited by 80 · see citing works

Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling

Ploeger, B. A., van der Graaf, P. H., & Danhof, M. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.3 · Cited by 78 · see citing works

Pharmacokinetics and Pharmacodynamics of Biotech Drugs

(2006) · Wiley eBooks · doi:10.1002/9783527609628 · Cited by 72 · see citing works

Assessing brain free fraction in early drug discovery

Read, K. D., & Braggio, S. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903559873 · Cited by 71 · see citing works

Model-based drug discovery: implementation and impact

Visser, S. A. G., Aurell, M., Jones, R. D. O., Schuck, V., Egnell, A., Peters, S. A., Brynne, L., Yates, J. W. T., Jansson‐Löfmark, R., Tan, B., et al. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.012 · Cited by 66 · see citing works

Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models

Wang, S., Guo, P., Wang, X., Zhou, Q. S., & Gallo, J. M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2070 · Cited by 59 · see citing works

Pharmacodynamics of morphine-induced neuronal nitric oxide production and antinociceptive tolerance development

Heinzen, E. L., & Pollack, G. M. (2004) · Brain Research · doi:10.1016/j.brainres.2004.07.015 · Cited by 53 · see citing works

Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development

Bernard, A., Kimko, H. H. C., Mital, D. P., & Poggesi, I. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.693480 · Cited by 53 · see citing works

Optimising in vivo pharmacology studies—Practical PKPD considerations

Gabrielsson, J., Green, A. R., & van der Graaf, P. H. (2010) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2010.02.002 · Cited by 52 · see citing works

Predicting Oral Clearance in Humans

Sinha, V. K., Buck, S. S. D., Fenu, L. A., Smit, J. W., Nijsen, M., Gilissen, R., Peer, A. V., Lavrijsen, K., & Mackie, C. E. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00004 · Cited by 49 · see citing works

The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives

Bueters, T., Ploeger, B. A., & Visser, S. A. G. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.001 · Cited by 43 · see citing works

Modeling and Simulation for Clinical Trial Design Involving a Categorical Response: A Phase II Case Study with Naratriptan

Nestorov, I., Graham, G., Duffull, S., Aarons, L., Fuseau, E., & Coates, P. (2001) · Pharmaceutical Research · doi:10.1023/a:1010943430471 · Cited by 41 · see citing works

Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys, and Humans

Gao, W., & Jusko, W. J. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042291 · Cited by 40 · see citing works

Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using In Vitro and Preclinical In Vivo Data

Heimbach, T., Lakshminarayana, S. B., Hu, W., & He, H. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9136-x · Cited by 35 · see citing works

Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor

Kamiya, N., Iwao, E., Hiraga, N., Tsuge, M., Imamura, M., Takahashi, S., Miyoshi, S., Tateno, C., Yoshizato, K., & Chayama, K. (2010) · Journal of General Virology · doi:10.1099/vir.0.019315-0 · Cited by 35 · see citing works

Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?

Beaumont, K. C., & Smith, D. A. (2009) · PubMed · Cited by 34 · see citing works

Pharmacodynamic Assessment of the Benztropine Analogues AHN-1055 and AHN-2005 Using Intracerebral Microdialysis to Evaluate Brain Dopamine Levels and Pharmacokinetic/Pharmacodynamic Modeling

Raje, S. V., Cornish, J. L., Newman, A. H., Cao, J., Katz, J. L., & Eddington, N. D. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-2488-8 · Cited by 31 · see citing works

Application of In Vivo Animal Models to Characterize the Pharmacokinetic and Pharmacodynamic Properties of Drug Candidates in Discovery Settings

Amore, B. M., Gibbs, J. P., & Emery, M. G. (2010) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620710790596808 · Cited by 23 · see citing works

Population Pharmacokinetic Model of the Pregabalin-Sildenafil Interaction in Rats: Application of Simulation to Preclinical PK-PD Study Design

Bender, G., Gosset, J., Florian, J., Tan, K., Field, M. J., Marshall, S. F., DeJongh, J., Bies, R. R., & Danhof, M. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9942-y · Cited by 16 · see citing works

Pharmacokinetic–pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior

Geldof, M., Freijer, J. I., van Beijsterveldt, L., Vermote, P. C. M., Megens, A. A. H. P., & Danhof, M. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.07.004 · Cited by 5 · see citing works

Mechanism-Based PKPD Projections in Exploratory Drug Development

Kawai, R. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.1 · Cited by 1 · see citing works

Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design

Vora, L. K., Gholap, A. D., Jetha, K. L., Singh, T. R. R., Solanki, H. K., & Chavda, V. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071916 · Cited by 1,152 · see citing works

A multi-organ chip with matured tissue niches linked by vascular flow

Ronaldson-Bouchard, K., Teles, D., Yeager, K., Tavakol, D. N., Zhao, Y., Chramiec, A., Tagore, S., Summers, M., Stylianos, S., Tamargo, M., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00882-6 · Cited by 512 · see citing works

Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare

Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., da Silva, I. C. B., Magalhães, P., Schmidt, S., & Vale, N. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030332 · Cited by 400 · see citing works

The Bioavailability of Drugs—The Current State of Knowledge

Stielow, M., Witczyńska, A., Kubryń, N., Fijałkowski, Ł., Nowaczyk, J., & Nowaczyk, A. (2023) · Molecules · doi:10.3390/molecules28248038 · Cited by 426 · see citing works

Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases

Ahmad, A., Imran, M., & Ahsan, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061630 · Cited by 405 · see citing works

Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development

Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299 · see citing works

Natural bioactive products as promising therapeutics: A review of natural product-based drug development

Aware, C. B., Patil, D. N., Suryawanshi, S. S., Mali, P., Rane, M. R., Gurav, R. G., & Jadhav, J. P. (2022) · South African Journal of Botany · doi:10.1016/j.sajb.2022.05.028 · Cited by 241 · see citing works

Computational oncology — mathematical modelling of drug regimens for precision medicine

Barbolosi, D., Ciccolini, J., Lacarelle, B., Barlési, F., & André, N. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.204 · Cited by 221 · see citing works

Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery

Lucas, A. J., Sproston, J. L., Barton, P., & Riley, R. J. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1660642 · Cited by 144 · see citing works

The application of isatin-based multicomponent-reactions in the quest for new bioactive and druglike molecules

Brandão, P., Marques, C. S., Burke, A. J., & Piñeiro, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113102 · Cited by 125 · see citing works

Intravital imaging to study cancer progression and metastasis

Entenberg, D. R., Oktay, M. H., & Condeelis, J. S. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00527-5 · Cited by 111 · see citing works

The Hitchhiker’s Guide to Human Therapeutic Nanoparticle Development

Ramos, T. I., Villacis-Aguirre, C. A., López-Aguilar, K. V., Padilla, L. S., Altamirano, C., Toledo, J. R., & Vispo, N. S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020247 · Cited by 111 · see citing works

Delivering on the promise of protein degraders

O’Brien, M. N., Luthra, S. A., Brown, M. F., & Bartlett, D. W. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00652-2 · Cited by 108 · see citing works

Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy

Pan, S., Zhang, Y., Natalia, A., Lim, C. Z. J., Ho, N. R. Y., Chowbay, B., Loh, T. P., Tam, J. K. C., & Shao, H. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00872-w · Cited by 103 · see citing works

Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety

Reichel, A., & Lienau, P. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_26 · Cited by 100 · see citing works

Lessons Learned from Two Decades of Anticancer Drugs

Liu, Z., Delavan, B., Roberts, R. A., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 95 · see citing works

Dendrimers as nanoscale vectors: Unlocking the bars of cancer therapy

Dey, A. D., Bigham, A., Esmaeili, Y., Ashrafizadeh, M., Moghaddam, F. D., Tan, S. C., Yousefiasl, S., Sharma, S., Maleki, A., Rabiee, N., et al. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.06.003 · Cited by 88 · see citing works

Machine learning approaches and their applications in drug discovery and design

Priya, S., Tripathi, G., Singh, D. B., Jain, P., & Kumar, A. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14057 · Cited by 89 · see citing works

Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19

Konig, M. F., Kim, A. H. J., Scheetz, M. H., Graef, E. R., Liew, J. W., Simard, J. F., Machado, P., Gianfrancesco, M. A., Yazdany, J., Langguth, D., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217690 · Cited by 83 · see citing works

Engineered tissues and strategies to overcome challenges in drug development

Khalil, A. S., Jaenisch, R., & Mooney, D. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.012 · Cited by 74 · see citing works

The Role of Extracellular Binding Proteins in the Cellular Uptake of Drugs: Impact on Quantitative In Vitro -to- In Vivo Extrapolations of Toxicity and Efficacy in Physiologically Based Pharmacokinetic-Pharmacodynamic Research

Poulin, P., Burczynski, F. J., & Haddad, S. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24571 · Cited by 74 · see citing works

Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations

Watt, G. F., Scott‐Stevens, P., & Gaohua, L. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.02.005 · Cited by 72 · see citing works

Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology

Garralda, E., Dienstmann, R., & Tabernero, J. M. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_180460 · Cited by 61 · see citing works

Improving preclinical studies through replications

Drude, N., Martinez‐Gamboa, L., Danziger, M., Dirnagl, U., & Toelch, U. (2021) · eLife · doi:10.7554/elife.62101 · Cited by 54 · see citing works

Accelerated Predictive Healthcare Analytics with Pumas, A High Performance Pharmaceutical Modeling and Simulation PlatformPreprint

Rackauckas, C., Ma, Y., Noack, A., Dixit, V., Mogensen, P. K., Elrod, C., Tarek, M., Byrne, S., Maddhashiya, S., Calderón, J. B. S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.28.402297 · Cited by 58 · see citing works

Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection

Arnold, S. L. M., Choi, R., Hulverson, M. A., Schaefer, D. A., Vinayak, S., Vidadala, R. S. R., McCloskey, M. C., Whitman, G. R., Huang, W., Barrett, L. K., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix247 · Cited by 57 · see citing works

Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models

Zdesenko, G., & Mutapi, F. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0008649 · Cited by 56 · see citing works

Dendrimers toward Translational Nanotherapeutics: Concise Key Step Analysis

Mignani, S. M., Shi, X., Rodrigues, J., Roy, R., Muñoz‐Fernández, M. Á., Ceña, V., & Majoral, J. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00395 · Cited by 56 · see citing works

Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference

Şahin, M., Henske, E. P., Manning, B. D., Ess, K. C., Bissler, J. J., Klann, E., Kwiatkowski, D. J., Roberds, S. L., Silva, A. J., Hillaire‐Clarke, C. S., et al. (2016) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2016.03.015 · Cited by 52 · see citing works

Enhancement of Immune Effector Functions by Modulating IgG’s Intrinsic Affinity for Target Antigen

Mazor, Y., Yang, C., Borrok, M. J., Ayriss, J. E., Aherne, K., Wu, H., & Dall’Acqua, W. F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157788 · Cited by 52 · see citing works

Practical solutions for including sex as a biological variable (SABV) in preclinical neuropsychopharmacological research

Dalla, C., Jarić, I., Pavlidi, P., Hodes, G. E., Kokras, N., Bespalov, A., Kas, M. J., Steckler, T., Kabbaj, M., Würbel, H., et al. (2023) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2023.110003 · Cited by 50 · see citing works

Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

McEntee, L., Johnson, A., Farrington, N., Unsworth, J., Dane, A. L., Jain, A., Cotroneo, N. S., Critchley, I. A., Melnick, D., Parr, T., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00603-19 · Cited by 50 · see citing works

What Are the Current Approaches to Optimising Antimicrobial Dosing in the Intensive Care Unit?

Chai, M. G., Cotta, M. O., Abdul-Aziz, M. H., & Roberts, J. A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070638 · Cited by 47 · see citing works

Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis

Ernest, J. P., Strydom, N., Wang, Q., Zhang, N., Nuermberger, E. L., Dartois, V. A., & Savić, R. M. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030920-011143 · Cited by 46 · see citing works

Medicinal plants for in vitro antiplasmodial activities: A systematic review of literature

Lemma, M. T., Ahmed, A. M., Elhady, M. T., Ngo, H. T., Vu, T. L.-H., Sang, T. K., Campos‐Alberto, E., Sayed, A., Mizukami, S., Na‐Bangchang, K., et al. (2017) · Parasitology International · doi:10.1016/j.parint.2017.09.002 · Cited by 45 · see citing works

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia

Aslostovar, L., Boyd, A. L., Almakadi, M., Collins, T. J., Leong, D. P., Tirona, R. G., Kim, R. B., Julian, J. A., Xenocostas, A., Leber, B. F., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018015677 · Cited by 42 · see citing works

An extensive survey on the use of supervised machine learning techniques in the past two decades for prediction of drug side effects

Das, P., & Mazumder, D. H. (2023) · Artificial Intelligence Review · doi:10.1007/s10462-023-10413-7 · Cited by 41 · see citing works

The importance of pharmacokinetics and pharmacodynamics in antimicrobial drug development and their influence on the success of agents developed to combat resistant gram negative pathogens: A review

Palmer, M. E., Andrews, L. J., Abbey, T. C., Dahlquist, A., & Wenzler, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.888079 · Cited by 40 · see citing works

Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia

Alsultan, A., Alghamdi, W. A., Alghamdi, J., Alharbi, A., Aljutayli, A., Albassam, A. A., Almazroo, O. A., & Alqahtani, S. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.08.012 · Cited by 40 · see citing works

Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib

Lamba, M., Hutmacher, M., Furst, D. E., Dikranian, A. H., Dowty, M. E., Conrado, D. J., Stock, T. B., Nduaka, C. I., Cook, J., & Krishnaswami, S. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.576 · Cited by 38 · see citing works

Sequential Delivery of Doxorubicin and Zoledronic Acid to Breast Cancer Cells by CB[7]-Modified Iron Oxide Nanoparticles

Benyettou, F., Alhashimi, M., O’Connor, M. J., Pasricha, R., Brandel, J., Traboulsi, H., Mazher, J., Olsen, J., & Trabolsi, A. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b11423 · Cited by 35 · see citing works

A Microfluidic Perfusion Platform for In Vitro Analysis of Drug Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships

Guerrero, Y. A., Desai, D., Sullivan, C., Kindt, E. K., Spilker, M. E., Maurer, T. S., Solomon, D. E., & Bartlett, D. W. (2020) · The AAPS Journal · doi:10.1208/s12248-020-0430-y · Cited by 34 · see citing works

Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes

Choi, Y. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050417 · Cited by 34 · see citing works

In silico docking study of Limonoids from Azadirachta indica with pfpk5: A Novel Target for Plasmodium falciparum

Khanal, P., Mandar, B. K., Magadum, P., Patil, B. M., & Hullatti, K. (2019) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.514 · Cited by 31 · see citing works

Immunoaffinity LC–MS/MS for Quantitative Determination of A Free and Total Protein Target as A Target Engagement Biomarker

Zhang, H., Gu, H., Shipkova, P. A., Ciccimaro, E., Sun, H., Zhao, Q., & Olah, T. V. (2017) · Bioanalysis · doi:10.4155/bio-2017-0152 · Cited by 30 · see citing works

Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies

Peters, S. A., Petersson, C., Blaukat, A., Halle, J.-P., & Dolgos, H. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.01.002 · Cited by 28 · see citing works

Pharmacoinformatics approach for investigation of alternative potential hepatitis C virus nonstructural protein 5B inhibitors

Mirza, M. U., Ghori, N.-U.-H., Ikram, N., Adil, A. R., & Manzoor, S. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s75886 · Cited by 29 · see citing works

Analyzing the Potential Root Causes of Variability of Pharmacokinetics in Preclinical Species

Daublain, P., Feng, K., Altman, M. D., Martin, I. J., Mukherjee, S. K., Nofsinger, R., Northrup, A. B., Tschirret-Guth, R. A., Cartwright, M. E., & McGregor, C. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01118 · Cited by 28 · see citing works

Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme

Hamilton, M. M., Mseeh, F., McAfoos, T. J., Leonard, P. G., Reyna, N. J., Harris, A. L., Xu, A., Han, M., Soth, M., Czakó, B., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00679 · Cited by 28 · see citing works

Pharmacokinetics and biopharmaceutics: “a leader or attendant”

Rajpoot, K., Tekade, R. K., Sharma, M. C., & Tekade, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814425-1.00020-6 · Cited by 27 · see citing works

Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective

Wong, H., Bohnert, T., Damian-Iordache, V., Gibson, C., Hsu, C.-P., Krishnatry, A. S., Liederer, B. M., Lin, J., Lu, Q., Mettetal, J. T., et al. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.04.015 · Cited by 27 · see citing works

HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies

Pasqua, E., Sharp, S. Y., Chessum, N. E. A., Hayes, A., Pellegrino, L., Tucker, M. J., Miah, A., Wilding, B., Evans, L. E., Rye, C. S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00156 · Cited by 27 · see citing works

A Survey of Software Tool Utilization and Capabilities for Quantitative Systems Pharmacology: What We Have and What We Need

Ermakov, S., Schmidt, B. J., Musante, C. J., & Thalhauser, C. J. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12373 · Cited by 26 · see citing works

Plasma Protein Binding of Highly Bound Drugs Determined With Equilibrium Gel Filtration of Nonradiolabeled Compounds and LC-MS/MS Detection

Isbell, J. J., Yuan, D., Torrao, L. R. D. S., Gatlik, E., Hoffmann, L., & Wipfli, P. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.004 · Cited by 25 · see citing works

Discovery of new benzothiazole-1,2,3-triazole hybrid-based hydrazone/thiosemicarbazone derivatives as potent EGFR inhibitors with cytotoxicity against cancer

Aljuhani, A., Nafie, M. S., Albujuq, N. R., Alsehli, M., Bardaweel, S. K., Darwish, K. M., Al‐Raqa, S. Y., Aouad, M. R., & Rezki, N. (2025) · RSC Advances · doi:10.1039/d4ra07540d · Cited by 25 · see citing works

Bacterial Quorum-Sensing Molecules as Promising Natural Inhibitors of Candida albicans Virulence Dimorphism: An In Silico and In Vitro Study

Jothi, R., Prasath, N. H., Gowrishankar, S., & Pandian, S. K. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.781790 · Cited by 24 · see citing works

Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis

Mallikaarjun, S., Chapagain, M. L., Sasaki, T., Hariguchi, N., Deshpande, D., Srivastava, S., Berg, A. K., Hirota, K., Inoue, Y., Matsumoto, M., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01207-20 · Cited by 24 · see citing works

Advances in reversible covalent kinase inhibitors

Zhao, Z., & Bourne, P. E. (2024) · Medicinal Research Reviews · doi:10.1002/med.22084 · Cited by 23 · see citing works

Strategic Priorities for Research on Antibiotic Alternatives in Animal Agriculture—Results From an Expert Workshop

Kurt, T. D., Wong, N. M., Fowler, H. N., Gay, C. G., Lillehoj, H. S., Plummer, P. J., Scott, H. M., & Hoelzer, K. (2019) · Frontiers in Veterinary Science · doi:10.3389/fvets.2019.00429 · Cited by 23 · see citing works

Optimizing Antimicrobial Therapy by Integrating Multi-Omics With Pharmacokinetic/Pharmacodynamic Models and Precision Dosing

Yow, H.-Y., Govindaraju, K., Lim, A. H., & Rahim, N. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.915355 · Cited by 22 · see citing works

Combined Bioinformatics and Combinatorial Chemistry Tools to Locate Drug‐Able Anti‐TB Phytochemicals: A Cost‐Effective Platform for Natural Product‐Based Drug Discovery

Swain, S. S., & Hussain, T. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200267 · Cited by 22 · see citing works

Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies

Wiesch, P. A. Z., Clarelli, F., & Cohen, T. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005321 · Cited by 22 · see citing works

Trends in iron oxide nanoparticles: a nano-platform for theranostic application in breast cancer

Halder, J., Pradhan, D., Biswasroy, P., Rai, V. K., Kar, B., Ghosh, G., & Rath, G. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2095389 · Cited by 21 · see citing works

Mitochondrial Imbalance of Trypanosoma cruzi Induced by the Marine Alkaloid 6-Bromo-2′-de-N-Methylaplysinopsin

Romanelli, M. M., Amaral, M., Thevenard, F., Cruz, L. M. S., Regasini, L. O., Migotto, Á. E., Lago, J. H. G., & Tempone, A. G. (2022) · ACS Omega · doi:10.1021/acsomega.2c03395 · Cited by 21 · see citing works

Comparative biophysical characterization: A screening tool for acetylcholinesterase inhibitors

Patil, D. N., Patil, S. A., Sistla, S., & Jadhav, J. P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215291 · Cited by 21 · see citing works

Application of a liquid chromatography–tandem mass spectrometry method to the pharmacokinetics, tissue distribution and excretion in the study of anemoside B4, a novel antiviral agent candidate, in rats

He, M., Ouyang, H., He, M., Tan, T., Li, J., Zhang, X., Jia, J., Feng, Y., & Yang, S. (2016) · Biomedical Chromatography · doi:10.1002/bmc.3914 · Cited by 20 · see citing works

Comparative physiology and efficacy of atropine and scopolamine in sarin nerve agent poisoning

Cornelissen, A. S., Klaassen, S. D., van Groningen, T., Bohnert, S., & Joosen, M. J. A. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.114994 · Cited by 20 · see citing works

Recent advances in the in vitro and in vivo methods to assess impact of P‐glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition

Chatterjee, S., Deshpande, A. A., & Shen, H. (2023) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2345 · Cited by 19 · see citing works

Evaluation of pharmacokinetic‐pharmacodynamic relationships and selection of drug combinations for tuberculosis

Muliaditan, M., & Pasqua, O. E. D. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14371 · Cited by 19 · see citing works

Pharmacokinetics and population pharmacokinetics in pediatric oncology

Sassen, S. D. T., Zwaan, C. M., van der Sluis, I. M., & Mathôt, R. A. A. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28132 · Cited by 19 · see citing works

PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse‐Type Tenosynovial Giant Cell Tumor

Smart, K. A., Bröske, A.-M. E., Rüttinger, D., Mueller, C., Phipps, A., Walz, A., Ries, C. H., Baehner, M., Cannarile, M. A., & Meneses‐Lorente, G. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1964 · Cited by 19 · see citing works

Mathematical modeling of receptor occupancy data: A valuable technology for biotherapeutic drug development

Spilker, M. E., Singh, P., & Vicini, P. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21318 · Cited by 19 · see citing works

Population Pharmacokinetic‐Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS)

Araújo, A., Machado, H. S., de Pinho, P. G., Soares-da-Silva, P., & Falcão, A. C. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1560 · Cited by 18 · see citing works

Pyrrolizine/Indolizine-NSAID Hybrids: Design, Synthesis, Biological Evaluation, and Molecular Docking Studies

Abourehab, M. A. S., Alqahtani, A. M., Almalki, F. A., Zaher, D. M., Abdalla, A. N., Gouda, A. M., & Beshr, E. A. M. (2021) · Molecules · doi:10.3390/molecules26216582 · Cited by 18 · see citing works

Artificial Intelligence: Future Aspects in the Pharmaceutical Industry an Overview

Bairagi, A., Singhai, A., & Jain, A. (2024) · Asian Journal of Pharmacy and Technology · doi:10.52711/2231-5713.2024.00039 · Cited by 5 · see citing works

Chalcones and their B-aryl analogues as myeloperoxidase inhibitors: In silico, in vitro and ex vivo investigations

dos Santos, M. B., Marques, B. C., Ayusso, G. M., Garcia, M. A. R., Paracatu, L. C., Pauli, I., Bolzani, V. D. S., Andricopulo, A. D., Ximenes, V. F., Zeraik, M. L., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104773 · Cited by 17 · see citing works

Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: A candidate formulation for visceral leishmaniasis

Borborema, S. E. T., Osso, J. A., Tempone, A. G., de Andrade, H. F., & do Nascimento, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.004 · Cited by 16 · see citing works

A Microphysiological Cell-Culturing System for Pharmacokinetic Drug Exposure and High-Resolution Imaging of Arrays of 3D Microtissues

Lohasz, C., Loretan, J., Sterker, D., Görlach, E., Renggli, K., Argast, P., Frey, O., Wiesmann, M., Wartmann, M., Rausch, M., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.785851 · Cited by 16 · see citing works

Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones

Pelivan, K., Frensemeier, L. M., Kärst, U., Koellensperger, G., Heffeter, P., Keppler, B. K., & Kowol, C. R. (2018) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-0889-x · Cited by 16 · see citing works

Microfluidic Module for Real-Time Generation of Complex Multimolecule Temporal Concentration Profiles

Woodruff, K., & Maerkl, S. J. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04099 · Cited by 16 · see citing works

Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus

Chia, Y. L., Tummala, R., Tu, H., Rouse, T., Streicher, K. L., White, W. I., Morand, E. F., & Furie, R. A. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2054 · Cited by 15 · see citing works

Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model

Jones, R. D. O., Petersson, K., Tabatabai, A., Bao, L., Tomkinson, H. K., & Schuller, A. G. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0193 · Cited by 15 · see citing works

The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST

Reddy, V. P., Anjum, R., Grondine, M. R., Smith, A., Bhavsar, D., Barry, E., Guichard, S. M., Shao, W., Kettle, J. G., Brown, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2848 · Cited by 15 · see citing works

Meta-analysis of material properties influencing nanoparticle plasma pharmacokinetics

Macedo, B., Patel, M. N., Zaleski, M. H., Mody, P., Ma, X., Mei, P., Myerson, J. W., Brenner, J. S., & Glassman, P. M. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122951 · Cited by 14 · see citing works

New thiazole, thiophene and 2-pyridone compounds incorporating dimethylaniline moiety: synthesis, cytotoxicity, ADME and molecular docking studies

Metwally, H. M., Younis, N. M., Abdel‐Latif, E., & El‐Rayyes, A. (2024) · BMC Chemistry · doi:10.1186/s13065-024-01136-z · Cited by 14 · see citing works

Pharmacokinetics and disposition of miltefosine in healthy mice and hamsters experimentally infected with Leishmania infantum

Jiménez-Antón, M. D., García‐Calvo, E., Gutiérrez, C., Escribano, M. D., Kayali, N., Luque-Garcia, J. L., Olías-Molero, A. I., Corral, M. J., Costi, M. P., Torrado, J. J., et al. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.06.002 · Cited by 14 · see citing works

Microfluidic technologies for local drug delivery

Hassan, S., & Zhang, Y. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812659-2.00010-7 · Cited by 13 · see citing works

Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts

Monterrubio, C., Paco, S., Vilà-Ubach, M., Rodríguez, E., Glisoni, R. J., Lavarino, C. E., Schaiquevich, P. S., Sosnik, A., Mora, J., & Carcaboso, A. M. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1671-9 · Cited by 13 · see citing works

New light on ω-3 polyunsaturated fatty acids and diabetes debate: a population pharmacokinetic-pharmacodynamic modelling and intake threshold study

Wang, L., Huang, X., Sun, M., Zheng, T., Zheng, L., Lin, X., Ruan, J., & Lin, F. Y. (2024) · Nutrition and Diabetes · doi:10.1038/s41387-024-00262-w · Cited by 12 · see citing works

A Population Dynamic Energy Budget-Based Tumor Growth Inhibition Model for Etoposide Effects on Wistar Rats

Tosca, E. M., Pigatto, M. C., Costa, T. D., & Magni, P. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2568-9 · Cited by 12 · see citing works

Developments in drug design strategies for bromodomain protein inhibitors to target Plasmodium falciparum parasites

Nguyen, H. H. T., Yeoh, L. M., Chisholm, S. A., & Duffy, M. F. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1704251 · Cited by 12 · see citing works

Ocular biodistribution of cysteamine delivered by a sustained release microsphere/thermoresponsive gel eyedrop

Jiménez, J., Resnick, J. L., Chaudhry, A. B., Gertsman, I., Nischal, K. K., & Fedorchak, M. V. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121992 · Cited by 11 · see citing works

Pharmacokinetic and Metabolomic Studies with a Promising Radiation Countermeasure, BBT-059 (PEGylated interleukin-11), in Rhesus Nonhuman Primates

Carpenter, A. D., Li, Y., Wise, S. Y., Fatanmi, O. O., Petrus, S. A., Fam, C. M., Carlson, S. J., Cox, G. N., Cheema, A. K., & Singh, V. K. (2024) · Radiation Research · doi:10.1667/rade-23-00194.1 · Cited by 11 · see citing works

The promise of Synovial Joint-on-a-Chip in rheumatoid arthritis

Zhang, X., Su, R., Wang, H., Wu, R., Fan, Y., Bin, Z., Gao, C., & Wang, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1408501 · Cited by 11 · see citing works

Structural and spectral properties of 4-(4-(1-(4-Hydroxyphenyl)-1-phenylethyl)phenoxy)phthalonitrile: Analysis by TD-DFT method, ADME analysis and docking studies

ALTUN, K., Yıldıko, Ü., Tanrıverdi, A. A., & Čakmak, İ. (2021) · International Journal of Chemistry and Technology · doi:10.32571/ijct.1004065 · Cited by 11 · see citing works

Male contraceptive development: A medicinal chemistry perspective

Norcross, N. R., Georgiou, I., Johnston, Z. C., Gruber, F. S., Swedlow, J. R., Read, K. D., Barratt, C. L. R., & Gilbert, I. H. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114709 · Cited by 11 · see citing works

Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model

Contreras-Sandoval, A. M., Merino, M., Vásquez, M., Trocóniz, I. F., Berraondo, P., & Garrido, M. J. (2016) · Oncotarget · doi:10.18632/oncotarget.12727 · Cited by 11 · see citing works

The pharmacological audit trail (PhAT): Use of tumor models to address critical issues in the preclinical development of targeted anticancer drugs

Rossanese, O. W., Eccles, S. A., Springer, C. J., Swain, A., Raynaud, F. I., Workman, P., & Kirkin, V. (2016) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2017.07.002 · Cited by 11 · see citing works

The Revolutionary Role of Artificial Intelligence (AI) in Pharmaceutical Sciences

Prusty, A., & Panda, S. K. (2024) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.58.3s.78 · Cited by 10 · see citing works

Upholding or Breaking the Law of Superposition in Pharmacokinetics

Yousef, M., Yáñez, J. A., Löbenberg, R., & Davies, N. M. (2024) · Biomedicines · doi:10.3390/biomedicines12081843 · Cited by 10 · see citing works

Pharmacokinetics and Pharmacodynamics: New Insights and Implication in Drug Development

Sahu, R. K., Kumari, K., Kumar, K., Kumar, M., Ansari, M. I., & Ahmad, S. (2025) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.15606215

Pharmacokinetics and biopharmaceutics: “a leader or attendant”

Rajpoot, K., Tekade, R. K., Sharma, M. C., & Tekade, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814425-1.00020-6 · Cited by 27 · see citing works

Pharmacokinetic-pharmacodynamic relationships in Phase I/Phase II of drug development

Peer, A. V., Snoeck, E., Huang, M., & Heykants, J. (1993) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03220008 · Cited by 17 · see citing works

Consistency of the pharmacodynamic index required for the decisions in drug discovery and drug development moving from the preclinical to the clinical studies

Shiotani, M. (2019) · Proceedings for Annual Meeting of The Japanese Pharmacological Society · doi:10.1254/jpssuppl.92.0_1-cs1-1

REVIEW ARTICLE

Tuntl, T., Ethell, B. T., Kosaka, T., Blasco, F., Zang, R. X., Jain, M., Gould, T. A., Hoffmaster, K. A., Mukhopadhyay, B., Tuntl, T., et al. (2014)